tbuckley/cabot-search huggingface dataset:
THU0123 Periarticular Demineralization as Measured by Digital X-Ray Radiogrammetry in Patients with Rheumatoid Arthritis – A Meta-Analysis
Authors: A. Pfeil, J. Böttcher, P. Oelzner, G. Wolf
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with periarticular bone loss. In the last decade Digital X-ray Radiogrammetry (DXR) was introduced to quantify periarticular bone loss. <h3>Objectives</h3> This Meta-analysis evaluates potential factors which influence periarticular bone loss as measured by DXR in patients with RA. <h3>Methods</h3> A systemic literature evaluation was performed to include studies that used DXR to measure cortical periarticular bone loss at the metacarpal bones (DXR-BMD) in RA-patients. Three independent researchers assessed the quality of the studies. DXR-BMD was compared to age, gender, disease duration, C-reactive Protein (CRP), the occurrence of rheuma factor and HAQ-DI (Health Assessment Questionnaire). <h3>Results</h3> 19 relevant studies, which fulfilled the inclusion criteria, included a quantity of 2673 RA-patients. Gender and age significantly influence DXR-BMD. A prolonged disease duration of RA was associated with a lower DXR-BMD. The Meta-analysis showed a reduced DXR-BMD (-3.3 %) in patients with elevated CRP-levels. Additionally, rheuma factor positive patients present a progressive loss of DXR-BMD. <h3>Conclusions</h3> This Meta-analysis revealed an impact of age and gender on DXR-BMD. In this way age and gender independent parameters of bone mineral density (e. g. T-Score) should be used. Additionally, the Meta-analysis clearly verified an obvious impact of high disease activity with a pronounced inflammatory activity on periarticular mineralisation resulting in a cortical metacarpal bone loss. Consequently, DXR seems to be a diagnostic tool to evaluate bone alteration related to disease activity in RA and functions as surrogate maker for radiological progression, may be optimizing the individual therapeutic strategies. <h3>Disclosure of Interest</h3> A. Pfeil Grant/research support from: Research Grant from Chugai Pharma Ltd, J. Böttcher: None Declared, P. Oelzner: None Declared, G. Wolf: None Declared
NOVEL HIGH-POTENCY ORAL ANTIPLATELET DRUGS VERSUS CLOPIDOGREL IN PATIENTS WITH DIABETES MELLITUS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A LARGE SINGLE-CENTER ALL-COMERS REGISTRY
Authors: Gennaro Giustino, Usman Baber, Melissa Aquino, George Dangas, Jason Kovacic, Pedro Moreno, Swathi Roy, Prakash Krishnan, Joseph Sweeny, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2015)
Abstract 4128: Serum insulin-like growth factor (IGF)-1 levels predict treatment efficacy of anti-angiogenic therapy for patients with advanced hepatocellular carcinoma (HCC)
Authors: Yu-Yun Shao, Chih-Hung Hsu, Chien-Chung Huang, Ann-Lii Cheng
Journal: Cancer Research (2011)

Abstract Background Patients with liver cirrhosis or HCC were found to have decreased serum IGF-1 levels. Serum IGF-1 levels have been shown to predict the prognosis of patients with various types of cancer. Whether the IGF-1 levels can predict the treatment efficacy of anti-angiogenic therapy for advanced HCC remained unknown. Methods Advanced HCC patients, enrolled in a phase II study (Hsu et al: J Hepatol 2010) and its extended cohort, were treated with sorafenib plus metronomic oral tegafur/uracil until disease progression. Serum samples were collected before treatment and 4 weeks after the start of treatment. The levels of IGF-1 and IGF-2 were determined by ELISA. The baseline levels and post-treatment changes of these factors were analyzed for their associations with treatment outcomes. Results Among 68 pts treated with the protocol treatment, 64 were enrolled to this study. Among them, 57 (89%) were male, 49 (72%) were chronically infected with hepatitis B virus, and 40 (63%) had extrahepatic metastasis. All patients had liver reserve graded as Child-Pugh class A. There were 4 partial responder (PR) and 33 patients with stable disease (SD) according to RECIST 1.0. The disease control rate (DCR, defined as PR+SD) was 58%. The median PFS and OS were 3.7 and 7.4 months, respectively. Both IGF-1 and IGF-2 levels significantly decreased after treatment (p &amp;lt; 0.001 and p &amp;lt; 0.001, respectively), but the post-treatment changes were not associated with treatment response or disease control. Patients with higher (≥ median) baseline IGF-1 levels, compared to those with lower levels, had significantly better disease control rates (DCR, 72% vs. 44%, p = 0.023) and longer PFS (median, 5.6 vs. 2.0 months, p = 0.034). OS was also longer in patients with higher baseline IGF-1 levels, but with borderline significance only (median, 8.1 vs. 5.0 months, p = 0.052). In multivariate analysis including all clinicopathologic variables with potential predictive values, high baseline IGF levels remained as an independent predictor for longer PFS (p = 0.008). Baseline IGF-2 levels were not found to be associated with treatment outcomes. Conclusions High baseline IGF-1 levels can predict better treatment efficacy of anti-angiogenic therapy for patients with advanced HCC. (This study was supported by the grant of NSC 98-3112-B-002-038.) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4128. doi:10.1158/1538-7445.AM2011-4128
Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis: Table 1
Authors: Mira Merashli, Gabriele De Marco, Mark Podgorski, Dennis McGonagle, Helena Marzo-Ortega
Journal: Annals of the Rheumatic Diseases (2016)

This is a repository copy of Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis.
Three-Phase Skeletal Scintigraphy in Pachydermoperiostosis
Authors: Sampath Santhosh, Anish Bhattacharya, Sanjay Bhadada, Ravinder Kaur, Mandeep Singh, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2011)

Pachydermoperiostosis or primary hypertrophic osteoarthropathy is a rare syndrome with diverse radiologic and clinical features. Though the diagnosis can be made on the basis of classic clinical radiologic features, it is often misdiagnosed due to the varied clinical presentations. We report a patient with pachydermoperiostosis in whom 3 phase skeletal scintigraphy played a significant role in establishing the diagnosis.
P370 CHOLESTATIC Abcb4-DEFICIENT MICE REVEAL DEPRESSION/ANXIETY-LIKE BEHAVIOR
Authors: K. Hochrath, S.M. Hölter, L. Garrett, V. Gailus-Durner, H. Fuchs, M. Hrabé de Angelis, W. Wurst, F. Lammert, C.S. Stokes
Journal: Journal of Hepatology (2014)
Esophageal Cancer Detection With Tc-99m Tetrofosmin SPECT
Authors: NAOYUKI WATANABE, TSUNEO HIRANO, YUMI FUKUSHIMA, MASASHI YUKIHIRO, KEIKO AOYAGI, KATSUMI TOMIYOSHI, TOMIO INOUE, KEIGO ENDO
Journal: Clinical Nuclear Medicine (1997)

Tc-99m tetrofosmin, a myocardial perfusion agent, may detect breast cancer. SPECT imaging with Tc-99m tetrofosmin was performed in a 66-year-old man who had esophageal carcinoma. Moderately increased uptake was shown in the esophagus due to a squamous cell carcinoma.
Intermittent treatment of hormone-dependent breast cancer using exemestane: translational research from lab bench to bedside.
Authors: S Masri, S Phung, C Chung, G Somlo, S Chen
Journal: Cancer Research (2009)

Abstract Abstract #3040 Background and Rationale: Endocrine therapy agents such as aromatase inhibitors (AIs) have shown good clinical efficacy in the treatment of post-menopausal breast cancer patients. Currently, the major clinical hindrance with endocrine therapy is disease progression or acquired resistance. Intermittent treatment of endocrine therapy agents has been proposed in several clinical trials to address whether this treatment strategy can delay the onset of acquired resistance in hormone-dependent breast cancers. To support these clinical trials, we have performed a pre-clinical study using the steroidal AI exemestane (EXE) to understand potential molecular features that differentiate continuous treatment of EXE from intermittent administration.&amp;#x2028; Methods: The ER+ and aromatase-overexpressing cell culture model system (MCF-7aro) was used in this pre-clinical study. The cells were treated either continuously (T+EXE Cont) or intermittently (T+EXE Interm) for 2 weeks with EXE and 1 week without EXE, in the presence of testosterone (T). In addition, a non-steroidal AI letrozole, was used in an identical intermittent manner.&amp;#x2028; Results: Based on cell culture studies, acquired resistance was reached at 14 weeks in the T+EXE Cont treated cells, while T+EXE Interm cells were still responsive to EXE. At 34 weeks, acquired resistance developed in the T+EXE Interm cell lines, which demonstrates a delay in time to progression. The non-steroidal AI letrozole did not demonstrate a delay in acquired resistance using this intermittent model. Based on microarray analysis, we observed that gene expression of certain estrogen-responsive genes was elevated in the T+EXE Cont cells, while select genes showed lower levels of up-regulation in T+EXE Interm lines.&amp;#x2028; Discussion: Based on our previous studies, up-regulation of a key estrogen-responsive gene, amphiregulin (AREG), is responsible for activating EGFR and mediating resistance to EXE. Expression of genes such as AREG are decreased in the T+EXE Interm cell lines, suggesting the suppression of growth factor signaling implicated in driving resistance. In addition, we have reported that EXE acts as an aromatase destabilizer at the protein level. Unlike letrozole or anastrozole, EXE-mediated protein degradation of aromatase may play a key role in reducing estrogen levels that are responsible for driving breast cancer survival and proliferation. Since these pre-clinical studies provide an important mechanistic basis for intermittent endocrine therapy, a clinical trial to evaluate the intermittent use of exemestane has been discussed and is planned to initiate in the near future. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3040.
P493Cardioprotective effect of melatonin on cardiac function and oxidative status in pulmonary arterial hypertension
Authors: G J Maarman, L Blauwet, D Blackhurst, K Sliwa, S Lecour
Journal: Cardiovascular Research (2014)

Purpose: Pulmonary arterial hypertension (PAH) is a disorder characterized by elevated pulmonary arterial pressure which leads to cardiac hypertrophy and dysfunction. Current treatments have marginal impact and additional therapies are required. Melatonin is a natural product shown to be cardioprotective against hypertension and myocardial ischemia. We propose that melatonin treatment may be cardioprotective in a model of monocrotaline (MCT) induced PAH. Methods: Male Long Evans rats (150-175g) were injected with MCT (80mg/kg) which induced PAH after 28 days. Melatonin (6mg/kg) was added in drinking water after 14 days of PAH development, until day 28 (n>5). Cardiac hypertrophy was confirmed with a ratio of the right ventricle weight over left ventricle plus septal weight (RVW/LV+S). Cardiac functional parameters were assessed at day 28, using isolated heart perfusion and echocardiography including right ventricular systolic (RVSP), developed pressure (RVDP) and left ventricular end diastolic volume (LVEDV). We also assessed plasma levels of oxidative stress (TBARS). Results: Melatonin reduced RVW/LV+S (0.56 ± 0.03 vs. 0.34 ± 0.03, p < 0.0006), RVSP (92.74 ± 5.13 mmHg vs. 79.82 ± 0.51mmHg, p < 0.0001) and RVDP (81.22 ± 2.75mmHg vs. 71.39 ± 0.57mmHg, p < 0.025). Melatonin also improved LVEDV (0.173 ± 0.01mL vs. 0.65± 0.08mL, p< 0.0002) and plasma TBARS (2.07 ± 0.28μM/mg protein vs. 1.25 ± 0.06μM/mg protein, p< 0.019). Conclusions: Our data suggest that melatonin improves cardiac function in far progressed experimental PAH by decreasing oxidative stress. Melatonin may represent a novel therapeutic approach in the treatment of PAH.
Abstract 519: Differential expression of basement membrane type IV collagen α chains as a prognostic factor of extrahepatic bile duct carcinoma
Authors: Ryuichi Karashima, Kotaro Hirashima, Ken-ichi Iyama, Yoshifumi Baba, Yoshikazu Sado, Yoshifumi Ninomiya, Hiroshi Takamori, Hideo Baba
Journal: Cancer Research (2010)

Abstract Objective: The destruction of the basement membrane is the first step of cancer cell invasion and metastasis. Type IV collagen is a major component of the basement membrane, and is composed of six genetically distinct α(IV) chains: α1(IV) to α6 (IV). The loss of α5/α6(IV) chains from the epithelial basement membrane at the early stage of cancer cell invasion has been reported in several types of cancers. However, the expression of α5/α6(IV) chains in extrahepatic bile duct carcinoma remains unclear. The expression status of α5/α6(IV) chains in extrahepatic bile duct carcinoma was examined. Methods: The expression of α(IV) chains, p53, and Ki-67 were examined by using immunohistochemical method in 36 surgical specimens of extrahepatic bile duct carcinoma. The relationship between clinicopathological parameters of 36 patients and the results of immunohistochemical staining was statistically examined using χ2 test or Fisher's exact test. The overall cancer-specific survival was estimated using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of the differences. Results: In the normal bile duct mucosa of all examined specimens, both α1/α2(IV) and α5/α6(IV) chains were stained in the basement membrane of the surface columnar epithelium in a continuous linear pattern, while both α3(IV) and α4(IV) chains were not stained. The α1/α2(IV) and α5/α6(IV) chains were also expressed in the basement membrane of smooth muscle cells of the muscularis propria and large blood vessels. In extrahepatic bile duct carcinoma, α5/α6(IV) chains disappeared partially or completely around the tubular cancer cells in 25 of 36 specimens. All of tumors expressed α5/α6(IV) chains were also positive for α1/α2(IV) chains. The expression of α5/α6(IV) chains were significantly correlated to T classification and TNM staging, and inversely correlated to p53 expression. No relationship was observed between the expression of α5/α6(IV) chains and Ki-67 index. The patients with loss of α1/2(IV) and α5/6(IV) chains demonstrated significantly poorer prognosis than those with positive α1/2(IV) chains, irrespective of α5/6(IV) expression. Conclusion: The loss of α1/2(IV) and α5/α6(IV) chains might be a useful prognostic factor for extrahepatic bile duct carcinoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 519.
COMPARATIVE LEFT VENTRICULAR MECHANICAL ACTIVATION OF TAKOTSUBO CARDIOMYOPATHY TO ACUTE ANTERIOR MI UTILIZING 2D STRAIN IMAGING
Authors: Mohamed Ahmed, Mayank Sardana, Rasla Somwail, Jorge Escobar, Josiah Bote, Mark Coelho, Aline Iskandar, Timothy Fitzgibbons, Gerard Aurigemma
Journal: Journal of the American College of Cardiology (2016)
P5-19-07: The Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.
Authors: J Chen, LJ Wu, P Shen, LF Yu, S Huang
Journal: Cancer Research (2011)

Abstract Purpose Docetaxel-based combination treatment has known to be effective for breast cancer. Genotyping of ABCC2 and SLCO1B3 were demonstrated determining the risk of docetaxel-induced leucopenia in other ethnic. We designed this phase II trial to evaluate single nucleotide polymorphisms (SNPs) of the two genes association with docetaxel haematological toxicity in chemonaive breast cancer patients of chinese population. Patients and Methods We selected 45 breast cancer patients who received docetaxel combination chemotherapy, Genomic DNA was isolated from peripheral blood and detected polymorphisms in ABCC2 and SLCO1B3. Results All patients were evaluated for toxicity. 28 patients developed with grade 3 or 4 leukopenia, and 17 with grade 1 or 2 in nadir leukocyte from cycle 1 baseline. The combined analysis indicated a significant association of 9383C/G in ABCC2 (P = 0.002) and 5676A/G in SLCO1B3 (P = 0.005) with docetaxel induced ***leukopenia. Patients homozygous for the variant allele (GG) of SLCO1B3 5676A/G had significantly higher leukopenia compared to patients with AA/AG ***genotypes(P &amp;lt;0.05). Similar trend was observed for ABCC2 (9383C/G) with heterozygotes (CG) having the highest percentage decrease compared to those with CC/GG genotypes(P = 0.06). Conclusion The study indicating that SNPs in ABCC2 and SLCO1B3 may predict the risk of leukopenia induced by docetaxel chemotherapy in china breast cancer patients. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-19-07.
Abstract 2747: Application of a novel multi-locus test for genetic association incorporating gene-gene interaction suggests functionality for multiple susceptibility loci for prostate cancer
Authors: Julia G. Ciampa, Chris Holmes, Nilanjan Chatterjee
Journal: Cancer Research (2011)

Abstract The discovery of gene-gene interactions in genome-wide association studies (GWAS) can generate hypotheses about the biologic process through which multiple susceptibility loci influence the pathogenesis of disease. We present an extension of a previously proposed score-test for disease association that allows for interaction between sets of biologically similar single nucleotide polymorphism (SNPs). The score-test gains power over alternative methods by incorporating a parsimonious one-degree-of-freedom model for gene-gene interaction. Our proposed extension allows for additional power gains in case-control studies via use of a retrospective likelihood that can exploit an assumption of gene-gene independence for the underlying population between unlinked sets of SNPs. Simulation studies were used to validate the performance of this method. It was found to maintain type I error and to gain power over alternative methods. We used it in a prostate cancer (PRCA) application with data from Stage II of the Cancer Genetic Markers of Susceptibility GWAS that includes 27,383 SNPs in 3941 cases and 3964 controls. We performed two genome scans, conditioning on established susceptibility SNPs for PRCA. Both analyses identified a high-ranking SNP notable for its biology and worthy of follow-up study. The first scan involved a sub-region of 8q24 that contains independent susceptibility loci specific to PRCA, as well as androgen-receptor (AR) binding sites and androgen-responsive enhancer elements. The analysis highlights rs748120 intronic to NR2C2 which produces an AR co-regulator such that, when NR2C2 binds AR, expression of their target genes decreases. The observed interaction suggests NR2C2 may contribute to the androgen sensitivity of this 8q24 gene desert in the etiology of PRCA. The second scan involved the JAZF1 and HNF1B genes regions that are associated with both PRCA and type 2 diabetes, which itself is associated with PRCA risk. The analysis highlights rs4810671 intronic to SULF2 which has demonstrated oncogenic properties in several cancers. It is regulated by insulin, the hormone thought to mediate the association of type 2 diabetes with PRCA. The observed interaction suggests abnormal insulin function may affect PRCA risk through dysregulation of SULF2. In summary, we propose an innovative multi-locus test for disease association that gains power over alternative methods and we describe promising results from a PRCA GWAS that suggest functionality for susceptibility regions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2747. doi:10.1158/1538-7445.AM2011-2747
P65 Oral anti-viral therapy shaping the indications for hepatitis B liver transplantation over 2 decades
Authors: Y. H. Oo, B. Gunson, D. J. Mutimer
Journal: Gut (2011)

<h3>Introduction</h3> Hepatitis B virus (HBV) infection is a major cause of liver disease. Nearly 350 million worldwide have chronic infection and around 600 000 persons die each year from consequences of HBV. Liver transplantation (LT) is an excellent treatment for HBV-related cirrhosis and hepatocellular carcinoma (HCC). Oral-antiviral therapy is effective in suppressing HBV replication. Before the introduction of oral anti-viral therapy the indications for LT were mainly fulminant liver failure (FHF) and hepatic decompensation. However, with availability of effective oral antiviral medication, there has been a change in the indication for LT in HBV infected patients, and the largest proportion has well compensated cirrhosis with HCC. <h3>Aim</h3> To analyse the indication and outcome of LT for HBV patients in our unit over 24 years. <h3>Method</h3> Retrospective database analysis of HBV related LT from 1986 to 2010. Indications, demographics, viral load, co-infection, oral anti-viral therapy, and outcome were examined. <h3>Results</h3> 121 patients with HBV were transplanted. 18 recipients were female, average age at time of transplant was 50. 36 were Asian, 8 were of African descent. Lamivudine prophylaxis for viral load suppression was usually used for those who were transplanted after year 1993 and median viral load pre-LT for this patient group was 10<sup>3</sup> (range 10<sup>2</sup>–10<sup>6</sup>) copies/ml. 58/121 had LT between 2000 and 2010, and 63 before 2000. 12.6% (8/63) had LT for FHF before year 2000, and only 7%(4/58) since 2000 (p=0.2). 14 (22%) transplanted pre-2000 and 31 (54%) post-2000 had HCC (p&lt;0.001). Median pre-LT bilirubin was 57 mmol/l (pre-2000) vs 31 (post-2000) (p=0.003) and median pre-LT INR was 1.7 (pre-2000) vs 1.2 (p&lt;0.001) but pre-LT creatinine was not significant between two groups. Three patients had regraft (1=HAT; 1=PNF; 1=recurrence). There were 9 deaths related to recurrent HBV in patients transplanted pre-2000 and 1 death in patients transplanted post 2000. There are three recurrent HCC pre 2000 and five recurrent HCC post-2000. The difference in survival between the two groups approaches statistical significance (p=0.13). 69 patients are alive, eight patients are followed abroad. All patients were treated with Lamivudine post-LT. Since 2000, Lamivudine was used in combination with Adefovir for 11 patients and Tenofovir for three patients pre-LT to suppress viral replication. One patient was on Entecavir pre-LT. <h3>Conclusion</h3> There is a change in the indication for LT in HBV patients since the introduction of oral antiviral therapy. An increasing proportion has well compensated liver disease with HCC as the indication for LT.
787 PREVALENCE OF PERSONALITY DISORDER IN SPANISH PENITENTIARY POPULATION. SUBANALYSIS OF PERSEO STUDY
Authors: A. Marco Mouriño, J.J. Anton Basanta, P. Sainz de la Hoya, J. de Juan Ramirez, I. Faraco, C Alia, G Almada, F Amaya, JJ Antón, M Bedia, J Borrego, E Campo, A Carreño, A da Silva, J de Juan, JR Díaz, J Domingo, I Faraco, V Ferrer, C Gallego, J García-Guerrero, C Gutierrez, AM Herrero, C Hoyos, G Jiménez-Gala'n, JM Laine, E Leandro, C López, A Marco, R Muros, F Paniagua, J Pérez de los Cobos, A Pérez-Valenzuela, R Planella, E Pozo, JR Rebolledo, F Ruíz, P Saíz de la Hoya, P Sánchez-Arrobas, C Sarriera, C Solé, J Trujols, LC Vasallo, M Veiras, C Yllobre, J Zúñiga
Journal: Journal of Hepatology (2013)